



PATENT

Attorney Docket No.: 3578-120

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Patent Application of : Group Art Unit: 1647  
Radmila Mileusnic, et al. : Examiner:  
: Jegatheesan Seharaseyon  
Serial No: 09/998,491 :  
Filed: November 30, 2001 : Confirmation No. 6361  
For: POLYPEPTIDES AND THEIR USES :

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, submitted herewith are copies of the references listed in the accompanying form PTO-1449, except for any U.S. patents and published U.S. patent applications which may be listed.

The Examiner is respectfully requested to review the items listed on the PTO Form 1449 and make them of record in the instant application as required by M.P.E.P. §609. It is requested that the Examiner initial the enclosed duplicate substitute Form 1449, and return one copy to the undersigned.

<b>CERTIFICATE OF MAILING UNDER 37 C.F.R. 1.8(a)</b>	
I hereby certify that this paper, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date indicated below, with sufficient postage, as first class mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
BY	<u>Jennifer R. Hanna</u>
DATE:	<u>6/8/06</u>

This Information Disclosure Statement should not be construed as a representation that the cited references are material or prior art, or that more relevant references do not exist.

This Statement is being submitted after receipt of an office action on the merits. The fee (\$180.00) in satisfaction of 37 C.F.R. § 1.17(p) is submitted herewith. Authorization is provided to charge any additional fee due in connection with this submission to deposit account 50-0573.

Respectfully submitted,

RADMILA MILEUSNIC, *ET AL.*

BY 

DANIEL A. MONACO

Reg. No. 30,480

DRINKER BIDDLE & REATH LLP

One Logan Square

18<sup>th</sup> and Cherry Streets


Philadelphia, PA 19103-6996

Tel.: (215) 988-3312

Fax: 215) 988-2757

*Attorney for the Applicants*

SUBSTITUTE FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
3578-120SERIAL NO.  
09/998,491

## INFORMATION DISCLOSURE STATEMENT

APPLICANT:  
Radmila Mileusnic, et al.FILING DATE  
November 30, 2001GROUP  
1647

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	AA	4,565,804	1/21/86	Rivier et al.	514	15	
	AB	4,810,636	3/7/89	Corey	435	14	
	AC	5,493,008	2/2/96	Fox et al.	530	326	
	AD	5,639,726	6/17/97	Lawrence et al.	514	12	
	AE	5,777,083	7/7/98	Burnie et al.	530	387.3	
	AF	6,214,797	4/10/01	Vale, Jr. et al.	514	12	

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AG	58-183656	10/26/83	Japan	C07C	103/52	Chem Abstract	
	AH	WO 00/069900	11/23/00	WIPO	C07K	1/107		

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AI	Kumagai, et al. "Construction of HIV Rev Peptides Containing Peptide Nucleic Acid That Bind HIV RRE IIB RNA", <i>Bioorganic &amp; Medicinal Chemistry Letters</i> 10 (2000) 377-379
AJ	Hojo, et al. "Protein Synthesis Using S-Alkyl Thioester of Partially Protected Peptide Segments. Synthesis of DNA-Binding Protein of <i>Bacillus stearothermophilus</i> , <i>Bull. Chem. Soc. Japan</i> , 65, 3055-3063 (1992)
AK	Gururaja, et al. "Candidacidal Activity Prompted by N-Terminus Histatin-Like Domain of Human Salivary Mucin (MUC7), <i>Biochimica et Biophysica Acta</i> 1431 (1999) 107-119
AL	On-Line Medical Dictionary "Derivative"
AM	Kirby, et al. "Y <sub>1</sub> and Y <sub>2</sub> Receptor Selective Neuropeptide Y Analogues: Evidence for a Y <sub>1</sub> Receptor Subclass", <i>J. Med. Chem.</i> 1995, 38, 4579-4586

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.